Overall, an increased expression of metalloproteinases, ACE, and MMP, which are known to degrade Aβ peptides and are associated with fibrosis, might contribute to lower Aβ-42 tissue levels in MASLD. Here, ACE is linked to metabolic dysfunction-associated steatotic liver disease.